OOIR: Observatory of International Research

Papers

(The H4-Index of RMD Open is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
CD73^low B-cell phenotypes and distinct cytokine profiles in patients with active anti-Jo-1 antibody positive idiopathic inflammatory myopathies	189
COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI – the French cohort study of SARS-CoV-2	85
Optical coherence tomography angiography detects retinal microvascular changes in giant cell arteritis: the potential protective role of aortitis	79
Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism	78
Assessment and personalised advice for fatigue in systemic lupus erythematosus using an innovative digital tool: the Lupus Expert system for the Assessment of Fatigue (LEAF) study	64
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study	64
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study	61
Correction: Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider	56
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis	56
Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan	51
Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study	50
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination	47
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2	45
Declaration on the use of social media for rheumatology professionals	45
Social media in advancing equity and collaboration in rheumatology: the CORDIALITY review	43
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study	42
Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study	41
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cr	41
Concordance and agreement between different activity scores in polymyalgia rheumatica	41
Antirheumatic treatment, disease activity and risk ofStaphylococcus aureusbacteraemia in rheumatoid arthritis: a nationwide nested case–control study	41
Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritis	40
Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry	39
Identification of variants in genes associated with autoinflammatory disorders in a cohort of patients with psoriatic arthritis	39
Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use	39
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry	38

Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupu	37
Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study	37
Tolerability of low to moderate biomechanical stress during leisure sport activity in patients with psoriasis and psoriatic arthritis	37
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 tri	37
Chronic abdominal aortic occlusive disease related to antiphospholipid syndrome: a rare presentation	36
History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis	36
Machine learning using genotype and gene-expression data identifies alterations of genes involved in infection susceptibility, antigen presentation and cytokine signalling as key contributors to JIA r	36
Still’s disease continuum from childhood to elderly: data from the international AIDA Network Still’s disease registry	35
Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry	35
Time sequence of autoimmune processes in the trajectory to rheumatoid arthritis development: what do we know?	34
Trends in work participation among patients with inflammatory rheumatic musculoskeletal diseases (iRMDs): Data from the German National Database (2010–2022)	34
Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis	34
Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study	34